Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Sponsor
UMC Utrecht
Study ID
NCT07276425
Status
Recruiting
Apply to this trial

Conditions

  • Prurigo Nodularis (PN)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dupilumab — DRUG
    In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.

Study Details

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Key Dates

Start date
Jun 1, 2025
Status verified
Dec 2025
Primary completion
Jun 1, 2028
Completion
Jun 1, 2028

Study Design

Enrollment
40 participants (estimated)

Primary Outcome Measure

Peak Pruritus NRS (PP-NRS) [ Time Frame: From enrollment to 52 weeks of treatment ]

Central Contacts

Related Studies